For research purposes only. Not for human consumption. Not medical advice.

Tirzepatide

Price updated daily

Weight Loss & Metabolic Health

Tirzepatide is a novel dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound) that acts on two incretin pathways simultaneously. Clinical trials demonstrate superior weight loss outcomes compared to semaglutide in head-to-head comparisons. Its dual mechanism also provides excellent glycemic control.

Research Use Cases

Superior weight loss vs. GLP-1 monotherapy
Type 2 diabetes management
Metabolic syndrome improvement
Cardiovascular risk reduction

Note: GI side effects common, especially during titration. Prescription required.